(AOF) – Abivax announces its intention to make a public offering of its ordinary shares, in the form of “American Depositary Shares (ADS)”, in the United States, subject to market and other conditions . The Company has confidentially submitted a draft registration document (Form F-1) to the Securities and Exchange Commission (SEC) in the United States. The timing, the number of new shares to be issued under the proposed offer and their price have not yet been determined.
AOF – LEARN MORE
Find out more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in financing by venture capital for start-ups. These companies are therefore obliged to carry out redundancy plans. Added to this is a much more restrictive regulatory framework. First, in the United States, the measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of the participants. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemicals) or 13 years (biologicals), with discounts that could range from 35 to 60% for biotechs. Similarly, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.
Source link -86